Experimental Studies on the Relative Efficacy of Dermatan Sulphate and Heparin as Antithrombotic Agents

Summary

In this study, the anticoagulant and antithrombotic properties of unfractionated heparin (UFH) and dermatan sulphate (DS) were compared. The ability of UFH and DS to impair thrombin generation in vitro and in ex vivo plasma samples was also studied. DS has minimal anticoagulant activity by conventional assays but impairs thrombin generation both in vitro and in ex vivo plasma samples. However, thrombin generation could not be suppressed below about 35% of control values at all doses of DS studied. While this was sufficient to impair experimental venous thrombosis during 10 minutes’ stasis, DS was ineffective in preventing thrombosis following 20 minutes’ stasis in doses up to 1.25 mg/kg. In contrast, 1 μg/ml of UFH completely suppressed thrombin generation in vitro, and 150 μg/kg prevented throm- bogenesis over a period of 20 minutes’ stasis. Neither drug prolonged the bleeding time (BT) at effective antithrombotic doses, but 2.5 mg/kg UFH significantly increased the BT, whereas DS did not. While DS has antithrombotic activity, it is less effective than UFH in inhibiting thrombin generation, and as an antithrombotic agent.

Keywords

Venous thrombosis - Dermatan sulphate - Heparin - Thrombin generation

• References

• 1 Barrowcliffe TW, Thomas DP. Antithrombin III and heparin. In: Haemostasis and Thrombosis. 2nd edn. p. 849 Bloom AL, Thomas DP. (eds). Churchill Livingstone; Edinburgh: 1987
• 2 Ofosu FA, Fernandez F, Gauthier D, Buchanan M. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulphate. Sem Thromb Haemostas 1985; 11: 1333-1337
• 3 Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and Factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
• 4 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin eofaetor II by dermatan sulphate. J Biol Cliem 1983; 258: 6713-6716
• 5 Ofosu FA, Modi GJ, Smith LM, Cerskus AL, Hirsh J, Blajchman MA. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 727-747
• 6 Johnson Edward A, Paterson MS. Lead precipitation: an aid to separation of dermatan and mucokeratan sulfates from glycosamino- glycan mixtures. Anal Biochem 1986; 158: 111-116
• 7 Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis inducing ability in human serum. J Appl Physiol 1959; 14: 943-946
• 8 Proctor RR, Rapaport SI. A partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 121-129
• 9 Thomas DP, Merton RE. A low molecular weight heparin compared with unfractionated heparin. Thrombos Res 1982; 28: 343-350
• 10 Eggleton CA, Barrowcliffe TW, Merton RE, Thomas DP. In vitro and in vivo studies of the anti-Xa activity of heparin. Thrombos Res 1981; 34: 319-328
• 11 Merton RE, Thomas DP, Havercroft SJ, Barrowcliffe TW, Lindahl U. High and low affinity heparin compared with unfractionated heparin as antithrombotic drugs. Thromb Haemostas 1984; 51: 254-256
• 12 Deykin D. The role of the liver in serum-induced hypercoagulability. J Clin Invest 1966; 45: 256-263
• 13 Aronson DL, Thomas DP. Experimental studies on venous thrombosis: effect of coagulants, procoagulants and vessel contusion. Thromb Haemostas 1985; 54: 866-870
• 14 Fernandez FA, Buchanan MR, Hirsh J, Fenton H JW, Ofosu FA. Catalysis of thrombin inhibition provides an index for estimating antithrombotic potential of glycosaminoglycans in rabbits. Thromb Haemostas 1987; 57: 286-293
• 15 Fernandez F, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. The haemorrhagic and antithrombotic effects of dermatan sulphate. Br J Haematol 1986; 64: 309-317
• 16 Ofosu FA, Blajchman MA, Modi GJ, Smith LM, Buchanan MR, Hirsh J. The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate. Br J Haematol 1985; 60: 695-704